Medical University of Vienna: Macular Degeneration trials

The registry lists 23 Macular Degeneration studies with Medical University of Vienna as lead sponsor. 6 are open to participants now and 1 have results posted.

Phase 2 2Phase 3 3Phase 4 1No phase 18(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Personalized Shared Eye-care Identification of Age-related Macular Degeneration Using Artificial Intelligence and Telemedicine by Matching Optometrist Office-based Sites With Clinical SupervisionNot yet recruitingNCT06465212
• Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease ProgressionRecruitingNCT06351670
• Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease ProgressionRecruitingNCT06351657
• Treatment of Neovascular AMD: Artificial Intelligence in Real-world SettingRecruitingNCT05093374Phase 4
• Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot StudyRecruitingNCT03921931Not applicable
• Aflibercept in Recurrent or Persistent CNVRecruitingNCT02669953
• Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular DegenerationCompletedNCT01027468Not applicableResults posted
• Imaging of the Angiofibrotic Switch in Neovascular AMDStatus unknownNCT03838679
• Non-invasive Optical Angiography in Age-related Macular DegenerationStatus unknownNCT02521142
• The Role of Complement Factor H Polymorphism in the Regulation of Choroidal Vascular Tone in Young Healthy SubjectsStatus unknownNCT02102880Not applicable
• Risk Factors for Drusen ProgressionWithdrawnNCT01830608
• Long-term Follow-up of Subfoveal Neovascular AMDStatus unknownNCT01608113
• Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular DegenerationCompletedNCT01162746Phase 2
• Macular Pigment Optical Density in Healthy SubjectsTerminatedNCT00993330
• Association Between Laser Interferometric Measurement of Fundus Pulsation and Pneumotonometric Measurement of Pulsatile Ocular Blood Flow in Patients With Age-related Macular DegenerationCompletedNCT00991666Not applicable
• Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular DegenerationCompletedNCT00879671Not applicable
• Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?WithdrawnNCT00813514Not applicable
• Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal NeovascularisationCompletedNCT00808197Not applicable
• The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head PerfusionTerminatedNCT00709657Not applicable
• An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control SubjectsCompletedNCT00709449Phase 2/3
• Does Complement Factor H Gene Polymorphism Play a Role in the Regulation of Vascular Tone in the Choroid?CompletedNCT00708929Not applicable
• Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal TriamcinoloneCompletedNCT00685100Phase 3
• Comparison of Reduced Fluence Versus Standard Photodynamic Therapy (in Combination With Intravitreal Triamcinolone Acetate)CompletedNCT00523406Phase 3